Atossa Therapeutics (NASDAQ:ATOS) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.38 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 704,919 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research report on Thursday, October 31st. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th.

Atossa Therapeutics Stock Performance

The company has a market capitalization of $188.64 million, a P/E ratio of -7.14 and a beta of 1.23. The business has a 50 day moving average price of $1.44 and a 200 day moving average price of $1.38.

Atossa Therapeutics (NASDAQ:ATOS) last posted its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts forecast that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.

Institutional Trading of Atossa Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after purchasing an additional 164,540 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares in the last quarter. Rhumbline Advisers bought a new stake in Atossa Therapeutics in the 2nd quarter valued at approximately $161,000. Finally, Virtu Financial LLC acquired a new position in Atossa Therapeutics during the 1st quarter worth approximately $151,000. 12.74% of the stock is owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.